SEC Form 3 filed by new insider Perceptive Advisors Llc
$IMTX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
1. Name and Address of Reporting Person*
(Street)
(Country) | 2. Date of Event Requiring Statement
(Month/Day/Year) 03/18/2026 | 3. Issuer Name and Ticker or Trading Symbol
Immatics N.V. [ IMTX ] | |||||||||||||||
| 3a. Foreign Trading Symbol
| 5. If Amendment, Date of Original Filed
(Month/Day/Year) | ||||||||||||||||
| 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| 6. Individual or Joint/Group Filing (Check Applicable Line)
| ||||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Ordinary Shares, nominal value EUR 0.01 per share | 10,383,456 | I | See Footnote(1)(6) |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Director Stock Option (Right to Buy) | (2) | 06/30/2030 | Ordinary Shares | 25,000 | $10 | I | See Footnote(5)(6) |
| Director Stock Option (Right to Buy) | (3) | 12/08/2031 | Ordinary Shares | 15,000 | $11 | I | See Footnote(5)(6) |
| Director Stock Option (Right to Buy) | 06/14/2023 | 06/13/2032 | Ordinary Shares | 25,000 | $7.94 | I | See Footnote(5)(6) |
| Director Stock Option (Right to Buy) | 06/27/2024 | 06/26/2033 | Ordinary Shares | 25,000 | $11.41 | I | See Footnote(5)(6) |
| Director Stock Option (Right to Buy) | 06/25/2025 | 06/24/2034 | Ordinary Shares | 40,000 | $12 | I | See Footnote(5)(6) |
| Director Stock Option (Right to Buy) | (4) | 06/23/2035 | Ordinary Shares | 41,500 | $5.44 | I | See Footnote(5)(6) |
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||||||
| Explanation of Responses: |
| 1. The securities are directly held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"). Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to the Master Fund. Joseph Edelman is the managing member of the Advisor. |
| 2. This option was granted on June 30, 2020 and is fully vested. |
| 3. This option was granted on December 9, 2021 and is fully vested. |
| 4. This option was granted on June 24, 2025 and will vest in full on the first anniversary of the grant date. |
| 5. Consists of options to purchase the Issuer's ordinary shares awarded to Adam Stone in connection with his role as a member of the Issuer's board of directors. Mr. Stone is the Chief Investment Officer of the Advisor. The Advisor may be deemed to have an indirect pecuniary interest in the options to purchase common stock of the Issuer reported herein because the Master Fund has the right to receive the director compensation provided in respect of Mr. Stone's board service through a partial management fee offset. |
| 6. The Advisor and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes. |
| /s/ Joseph Edelman - for Perceptive Advisors LLC, By: Joseph Edelman, its managing member | 03/18/2026 | |
| /s/ Joseph Edelman - for Perceptive Life Sciences Master Fund, Ltd., By: Perceptive Advisors LLC, its investment manager, By: Joseph Edelman, its managing member | 03/18/2026 | |
| /s/ Joseph Edelman | 03/18/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
| * Form 3: SEC 1473 (03-26) | ||